These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12181623)

  • 21. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
    Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
    Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alendronate for the treatment of osteoporosis in men.
    Orwoll E; Ettinger M; Weiss S; Miller P; Kendler D; Graham J; Adami S; Weber K; Lorenc R; Pietschmann P; Vandormael K; Lombardi A
    N Engl J Med; 2000 Aug; 343(9):604-10. PubMed ID: 10979796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
    Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of bone loss in paraplegics over 2 years with alendronate.
    Zehnder Y; Risi S; Michel D; Knecht H; Perrelet R; Kraenzlin M; Zäch GA; Lippuner K
    J Bone Miner Res; 2004 Jul; 19(7):1067-74. PubMed ID: 15176988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.
    Chesnut CH; McClung MR; Ensrud KE; Bell NH; Genant HK; Harris ST; Singer FR; Stock JL; Yood RA; Delmas PD
    Am J Med; 1995 Aug; 99(2):144-52. PubMed ID: 7625419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density.
    Khan A; Dubois S; Khan AA; Zohair Rahman M; Ahmed Khan O; Syed HT; Derzko C
    J Obstet Gynaecol Can; 2014 Nov; 36(11):976-982. PubMed ID: 25574674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis.
    Pennisi P; Pizzarelli G; Spina M; Riccobene S; Fiore CE
    J Bone Miner Metab; 2003; 21(6):402-8. PubMed ID: 14586797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
    Muratore M; Quarta L; Calcagnile F; Quarta E
    Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alendronate prevents further bone loss in renal transplant recipients.
    Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
    J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].
    Cheng ZQ; Yin W; Fan JY; Ma TJ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):306-9. PubMed ID: 12905641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
    Bettembuk P; Balogh A
    Orv Hetil; 1999 Dec; 140(50):2799-803. PubMed ID: 10647267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months.
    Heervä E; Huilaja L; Leinonen P; Peltonen S; Peltonen J
    Calcif Tissue Int; 2014 Jun; 94(6):608-12. PubMed ID: 24390519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.
    Morabito N; Catalano A; Gaudio A; Morini E; Bruno LM; Basile G; Tsiantouli E; Bellone F; Agostino RM; Piraino B; La Rosa MA; Salpietro C; Lasco A
    J Bone Miner Metab; 2016 Sep; 34(5):540-6. PubMed ID: 26204844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.
    Giusti A
    J Bone Miner Metab; 2014 Nov; 32(6):606-15. PubMed ID: 24748165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
    Abitbol V; Briot K; Roux C; Roy C; Seksik P; Charachon A; Bouhnik Y; Coffin B; Allez M; Lamarque D; Chaussade S
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1184-9. PubMed ID: 17683996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition.
    Haderslev KV; Tjellesen L; Sorensen HA; Staun M
    Am J Clin Nutr; 2002 Aug; 76(2):482-8. PubMed ID: 12145026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial.
    Piriyakhuntorn P; Tantiworawit A; Phimphilai M; Srichairatanakool S; Teeyasoontranon W; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Norasetthada L; Fanhchaksai K; Charoenkwan P
    Front Endocrinol (Lausanne); 2023; 14():1178761. PubMed ID: 37251676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.